Boston Sci to distribute Veniti’s venous stent

Boston Scientific
Boston Scientific will market Veniti's stent for the treatment of venous disease under a limited global distribution agreement. (Boston Scientific)

Veniti, which focuses on the treatment of venous disease, has inked a distribution deal with its investor, Boston Scientific. The devicemaker will distribute the former’s Vici Venous Stent under a limited global distribution agreement.

The companies did not disclose further details on the agreement.

Boston Sci took part in Veniti’s $25 million series D round in September 2016. Veniti pegged the funds to wrap up its 200-patient trial, run under an investigational device exemption from the FDA, of the Vici stent. The company raised $17 million in series C financing a year prior.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"The VICI VENOUS STENT is widely recognized as state-of-the-art technology for venous stents and physicians routinely praise the product for its performance qualities. We are extremely pleased to be partnering with a global industry leader like Boston Scientific to advance the VICI VENOUS STENT in the marketplace," said Veniti CEO Jeff Elkins, in a statement. "Boston Scientific's market leadership and reach will provide more physicians treating patients suffering from venous outflow obstruction around the world greater access to leading-edge technology."

The most common form of venous obstructive disease is deep-vein thrombosis, which affects as many as 900,000 Americans each year, according to CDC estimates. Patients are usually treated with anticoagulants, but a recent study found that a subset of patients may benefit from a combination approach of interventional treatment and clot-busting drugs.

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.